Author Topic: Covid Culture (was Outbreak Culture)  (Read 16009 times)

0 Members and 0 Guests are viewing this topic.

Offline wilber

  • Hero Member
  • *****
  • Posts: 5626
Re: Covid Culture (was Outbreak Culture)
« Reply #1995 on: October 15, 2020, 07:43:47 pm »
oh that's right; you were the guy repeatedly bashing the Trudeau government for not signing on with AstraZeneca... and then after it occurred, said it was, "too little, too late"!  ;D

how does your conspiracy line up with the U.S. signing a deal with AstraZeneca for 200 million doses... along with the manufacturing deals with the plants in NY and New Mexico... is that just "LittlePharma"?

wait, what!  ;D ... just throwin' member wilber a bone!

Canada has signed deal for AstraZeneca vaccine candidate: PM

They have manufacturing deals but the deal is they have to sell at cost for the duration of the pandemic.
"Never trust a man without a single redeeming vice" WSC

Offline waldo

  • Hero Member
  • *****
  • Posts: 3860
Re: Covid Culture (was Outbreak Culture)
« Reply #1996 on: October 16, 2020, 01:07:39 am »
They have manufacturing deals but the deal is they have to sell at cost for the duration of the pandemic.

no - the initial Oxford University pledge offering open rights (with presumptive resulting low or free cost of manufactured vaccines) to all/any pharmaceutical company fell apart once it made an exclusive deal with AstraZeneca... that exclusive deal with AstraZeneca gave the company, "sole rights and no guarantee of low prices—with the less-publicized potential for Oxford to eventually make millions from the deal and win plenty of prestige".

Oxford’s COVID vaccine deal with AstraZeneca raises concerns about access and pricing

AstraZeneca stock and options owned by CEO Pascal Soriot have increased by nearly $15 million in value since early April, according to calculations by KHN based on company disclosures. The stock hit an all-time high in July. The stock market value of Novavax, a biotech that never recorded a profit in more than two decades, soared tenfold to $10 billion after a nonprofit and the Trump administration agreed to give it $1.6 billion to make a vaccine.

After Oxford announced the exclusive AstraZeneca deal, the company said it would sell vaccines at no profit—but only during the pandemic. Johnson & Johnson’s pledge to earn no vaccine profit is similarly limited.

With financial information kept confidential, no one will be able to confirm whether the vaccines are truly being sold at cost. And if vaccine immunity is only temporary and endemic coronavirus strains require regular shots for years, the companies will make plenty of money down the road, critics say.

Under its deal with AstraZeneca, Oxford will receive no royalties during the pandemic but could make millions after it ends through a web of patents including those held by Vaccitech, a for-profit spinoff. Vaccitech’s ownership includes a 50% stake held directly or indirectly by Oxford and 5.25% each owned by Hill and Jenner’s other top vaccine scientist, Sarah Gilbert, U.K. regulatory filings show.

AstraZeneca, one of the U.K.’s two major pharma companies, may have demanded an exclusive license in return for doing a deal, said Ken Shadlen, a professor at the London School of Economics and an authority on pharma patents—a theory supported by comments from CEO Soriot.

“I think IP [intellectual property, or exclusive patents] is a fundamental part of our industry and if you don’t protect IP, then essentially there is no incentive for anybody to innovate,” Soriot told the newspaper The Telegraph in May.

If nothing else, governments and vaccine makers should be open about their relationships, including making contracts public, said Duncan Matthews, a patent law professor at the Queen Mary University of London.

“We simply don’t know what’s in these deals,” he said. “The biopharma industry is applying old rules of commercial confidentiality in a situation that is unprecedented.”